Literature DB >> 27504761

Cancer anabolic metabolism inhibitors move into clinic.

Ken Garber.   

Abstract

Entities:  

Year:  2016        PMID： 27504761     DOI： 10.1038/nbt0816-794

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Authors:  David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

2.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 3.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

4.  Reductive carboxylation supports growth in tumour cells with defective mitochondria.

Authors:  Andrew R Mullen; William W Wheaton; Eunsook S Jin; Pei-Hsuan Chen; Lucas B Sullivan; Tzuling Cheng; Youfeng Yang; W Marston Linehan; Navdeep S Chandel; Ralph J DeBerardinis
Journal:  Nature       Date:  2011-11-20       Impact factor: 69.504
  4 in total
  21 in total

Review 1.  Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis.

Authors:  Wentao Dong; Mark A Keibler; Gregory Stephanopoulos
Journal:  Metab Eng       Date:  2017-02-10       Impact factor: 9.783

2.  A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.

Authors:  Maria V Liberti; Ziwei Dai; Suzanne E Wardell; Joshua A Baccile; Xiaojing Liu; Xia Gao; Robert Baldi; Mahya Mehrmohamadi; Marc O Johnson; Neel S Madhukar; Alexander A Shestov; Iok I Christine Chio; Olivier Elemento; Jeffrey C Rathmell; Frank C Schroeder; Donald P McDonnell; Jason W Locasale
Journal:  Cell Metab       Date:  2017-09-14       Impact factor: 27.287

3.  SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.

Authors:  Kai Su Greene; Michael J Lukey; Xueying Wang; Bryant Blank; Joseph E Druso; Miao-Chong J Lin; Clint A Stalnecker; Chengliang Zhang; Yashira Negrón Abril; Jon W Erickson; Kristin F Wilson; Hening Lin; Robert S Weiss; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 4.  Targeting amino acid metabolism for cancer therapy.

Authors:  Michael J Lukey; William P Katt; Richard A Cerione
Journal:  Drug Discov Today       Date:  2016-12-14       Impact factor: 7.851

5.  The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.

Authors:  Deanna N Edwards; Verra M Ngwa; Shan Wang; Eileen Shiuan; Dana M Brantley-Sieders; Laura C Kim; Albert B Reynolds; Jin Chen
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

6.  Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.

Authors:  Larissa Menezes Dos Reis; Douglas Adamoski; Rodolpho Ornitz Oliveira Souza; Carolline Fernanda Rodrigues Ascenção; Krishina Ratna Sousa de Oliveira; Felipe Corrêa-da-Silva; Fábio Malta de Sá Patroni; Marília Meira Dias; Sílvio Roberto Consonni; Pedro Manoel Mendes de Moraes-Vieira; Ariel Mariano Silber; Sandra Martha Gomes Dias
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

7.  Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Authors:  Matthew S Waitkus; Christopher J Pirozzi; Casey J Moure; Bill H Diplas; Landon J Hansen; Austin B Carpenter; Rui Yang; Zhaohui Wang; Brian O Ingram; Edward D Karoly; Robert P Mohney; Ivan Spasojevic; Roger E McLendon; Henry S Friedman; Yiping He; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2017-11-02       Impact factor: 12.701

Review 8.  Glutamine Metabolism in Cancer: Understanding the Heterogeneity.

Authors:  Ahmad A Cluntun; Michael J Lukey; Richard A Cerione; Jason W Locasale
Journal:  Trends Cancer       Date:  2017-03

Review 9.  Tumour metabolism and its unique properties in prostate adenocarcinoma.

Authors:  David A Bader; Sean E McGuire
Journal:  Nat Rev Urol       Date:  2020-02-28       Impact factor: 14.432

Review 10.  Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy.

Authors:  Yung Lyou; Amber N Habowski; George T Chen; Marian L Waterman
Journal:  Br J Pharmacol       Date:  2017-08-24       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.